transmembrane protein 120AGenealiases: NET29 · TACAN · TMPIT
Q-omics provides the consensus-scored TMEM120A profile across patient tissues and cancer cell-line models. TMEM120A expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TMEM120A is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, TMEM120A RNA expression shows 16,583 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, COAD, and ACC as cancer lineages where TMEM120A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM120A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM120A survival associations across molecular data types. TMEM120A RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM120A RNA expression–survival associations across cancer types. High TMEM120A expression shows unfavorable associations in UVM, KICH, CESC, ACC and LGG, but favorable associations in MESO. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for TMEM120A RNA expression.
This table summarizes TMEM120A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TMEM120A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM120A shows lower tumor expression in COAD, KICH and UCEC and higher tumor expression in KIRC, LIHC and LUAD. The COAD box plot shows higher TMEM120A RNA expression in normal versus tumor tissue (log2 FC = −0.934, t-test p < 0.001).
This table shows molecular features associated with TMEM120A in patient tissues and cancer cell lines. In patient samples, TMEM120A shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM120A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and LIVER.
